Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267176 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,020
- Enrollment target
NCT00267176: Completed Phase 4 study, sponsored by Novartis Pharmaceuticals.
NCT00267176 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,020 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00267176, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,020 participants
- Enrollment target
Study Summary
This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.
Interventions
- DRUG lumiracoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2005-11 |
| Phase | Phase 4 |
What the finished NCT00267176 record still lists
NCT00267176 is an interventional study that assigns participants to a tested intervention. Its 1,020 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% higher).
The record links to 0 conditions, and to 1 intervention - of which lumiracoxib is the first listed.
NCT00267176 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00267176 about?
NCT00267176 is a clinical study titled "Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension". This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.
What is the current status of trial NCT00267176?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,020 participants. The study started on 2005-11.
What interventions are being tested in trial NCT00267176?
The interventions under investigation include: lumiracoxib (DRUG).
Who is sponsoring clinical trial NCT00267176?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00267176's enrollment target sits among peer trials
1,020 66th of 2000 higher than 1,935 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
- NCT05225428 · 1,020 participants · NA
Video Education With Result Dependent dIsclosure
- NCT06697600 · 1,020 participants · NA
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- NCT06760637 · 1,020 participants · Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia